Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement
- PMID: 31289964
- PMCID: PMC6616606
- DOI: 10.1186/s13244-019-0743-5
Imaging of non-neuronopathic Gaucher disease: recent advances in quantitative imaging and comprehensive assessment of disease involvement
Abstract
Gaucher disease is an inherited metabolic disorder resulting in deficiency of lysosomal enzyme β-glucocerebrosidase causing the accumulation of abnormal macrophages ("Gaucher cells") within multiple organs, most conspicuously affecting the liver, spleen, and bone marrow. As the most common glycolipid metabolism disorder, it is important for radiologists encountering these patients to be familiar with advances in imaging of organ and bone marrow involvement and understand the role of imaging in clinical decision-making. The recent advent of commercially available, reliable, and reproducible quantitative MRI acquisitions to measure fat fractions prompts revisiting the role of quantitative assessment of bone marrow involvement. This manuscript reviews the diverse imaging manifestations of Gaucher disease and discusses more optimal quantitative approaches to ascertain solid organ and bone marrow involvement with an emphasis on future applications of other quantitative methods including elastography.
Keywords: Bone marrow infiltration; Gaucher disease; Lysosomal storage disorder; Quantitative MRI; Treatment monitoring.
Conflict of interest statement
CF has received consulting fees and/or honoraria from Genzyme corporation, Pfizer Inc., and Shire Pharmaceutical, makers of therapies for Gaucher disease. The remaining authors declare that they have no competing interests.
Figures
Similar articles
-
The Spectrum of Neurological Manifestations Associated with Gaucher Disease.Diseases. 2017 Mar 2;5(1):10. doi: 10.3390/diseases5010010. Diseases. 2017. PMID: 28933363 Free PMC article. Review.
-
Clinical manifestations and management of Gaucher disease.Clin Cases Miner Bone Metab. 2015 May-Aug;12(2):157-64. doi: 10.11138/ccmbm/2015.12.2.157. Epub 2015 Oct 26. Clin Cases Miner Bone Metab. 2015. PMID: 26604942 Free PMC article. Review.
-
A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.J Neurosci. 2016 Jul 13;36(28):7441-52. doi: 10.1523/JNEUROSCI.0636-16.2016. J Neurosci. 2016. PMID: 27413154 Free PMC article.
-
Gaucher disease.J Clin Exp Hepatol. 2014 Mar;4(1):37-50. doi: 10.1016/j.jceh.2014.02.005. Epub 2014 Apr 21. J Clin Exp Hepatol. 2014. PMID: 25755533 Free PMC article. Review.
-
Is there a role for scintigraphic imaging of bone manifestations in Gaucher disease? A review of the literature.Nuklearmedizin. 2008;47(6):239-47. Nuklearmedizin. 2008. PMID: 19057797 Review.
Cited by
-
The Bone Biomarker of Quantitative Chemical Shift Imaging in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long-Term Enzyme Replacement Therapy.J Clin Med. 2023 Mar 13;12(6):2220. doi: 10.3390/jcm12062220. J Clin Med. 2023. PMID: 36983221 Free PMC article.
-
Neuronopathic Gaucher disease: Beyond lysosomal dysfunction.Front Mol Neurosci. 2022 Aug 3;15:934820. doi: 10.3389/fnmol.2022.934820. eCollection 2022. Front Mol Neurosci. 2022. PMID: 35992201 Free PMC article. Review.
-
Current and emerging pharmacotherapy for Gaucher disease in pediatric populations.Expert Opin Pharmacother. 2021 Aug;22(11):1489-1503. doi: 10.1080/14656566.2021.1902989. Epub 2021 Mar 25. Expert Opin Pharmacother. 2021. PMID: 33711910 Free PMC article.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
